|
|
Prepublished online as a Blood First Edition Paper on April 3, 2003; DOI 10.1182/blood-2002-06-1694.
 Previous Article | Table of Contents | Next Article 
Blood, 1 August 2003, Vol. 102, No. 3, pp. 881-886
HEMATOPOIESIS
Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells
Ewa Sitnicka,
Natalija Buza-Vidas,
Staffan Larsson,
Jens M. Nygren,
Karina Liuba, and
Sten Erik W. Jacobsen
From the Hematopoietic Stem Cell Laboratory, Lund Strategic Research Cnter for Stem Cell Biology and Cell Therapy, Lund University Hospital, Sweden
The cytokine tyrosine kinase receptors c-kit and flt3 are expressed and function in early mouse and human hematopoiesis. Through its ability to promote ex vivo expansion and oncoretroviral transduction of primitive human hematopoietic progenitors, the flt3 ligand (FL) has emerged as a key stimulator of candidate human hematopoietic stem cells (HSCs). However, recent studies in the mouse suggest that though it is present on short-term repopulating cells, flt3 is not expressed on bone marrow long-term reconstituting HSCs, the ultimate target for the development of cell replacement and gene therapy. Herein we demonstrate that though only a fraction of human adult bone marrow and cord blood CD34+long-term culture-initiating cells (LTC-ICs) express flt3, most cord blood lymphomyeloid HSCs capable of in vivo reconstituting nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice are flt3+. The striking difference in flt3 and c-kit expression on mouse and candidate human HSCs translated into a corresponding difference in flt3 and c-kit function because FL was more efficient than SCF at supporting the survival of candidate human HSCs. In contrast, SCF is far superior to FL as a viability factor for mouse HSCs. Thus, the present data provide compelling evidence for a contrasting expression and response pattern of flt3 and c-kit on mouse and human HSCs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Buza-Vidas, M. Cheng, S. Duarte, H. Nozad Charoudeh, S. E. W. Jacobsen, and E. Sitnicka
FLT3 receptor and ligand are dispensable for maintenance and posttransplantation expansion of mouse hematopoietic stem cells
Blood,
April 9, 2009;
113(15):
3453 - 3460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vempati, C. Reindl, U. Wolf, R. Kern, K. Petropoulos, V. M. Naidu, C. Buske, W. Hiddemann, T. M. Kohl, and K. Spiekermann
Transformation by Oncogenic Mutants and Ligand-Dependent Activation of FLT3 Wild-type Requires the Tyrosine Residues 589 and 591
Clin. Cancer Res.,
July 15, 2008;
14(14):
4437 - 4445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kikushige, G. Yoshimoto, T. Miyamoto, T. Iino, Y. Mori, H. Iwasaki, H. Niiro, K. Takenaka, K. Nagafuji, M. Harada, et al.
Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival
J. Immunol.,
June 1, 2008;
180(11):
7358 - 7367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chumsri, W. Matsui, and A. M Burger
Therapeutic Implications of Leukemic Stem Cell Pathways
Am. Assoc. Cancer Res. Educ. Book,
April 12, 2008;
2008(1):
397 - 406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chumsri, W. Matsui, and A. M. Burger
Therapeutic Implications of Leukemic Stem Cell Pathways
Clin. Cancer Res.,
November 15, 2007;
13(22):
6549 - 6554.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Vempati, C. Reindl, S. K. Kaza, R. Kern, T. Malamoussi, M. Dugas, G. Mellert, S. Schnittger, W. Hiddemann, and K. Spiekermann
Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential
Blood,
July 15, 2007;
110(2):
686 - 694.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al.
Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma
J. Clin. Oncol.,
September 20, 2005;
23(27):
6699 - 6711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Levis, K. M. Murphy, R. Pham, K.-T. Kim, A. Stine, L. Li, I. McNiece, B. D. Smith, and D. Small
Internal tandem duplications of the FLT3 gene are present in leukemia stem cells
Blood,
July 15, 2005;
106(2):
673 - 680.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. G. Wang, M. P. Pasillas, and M. P. Kamps
Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus
Blood,
July 1, 2005;
106(1):
254 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fukuda, H. E. Broxmeyer, and L. M. Pelus
Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1{alpha}(CXCL12)/CXCR4 axis
Blood,
April 15, 2005;
105(8):
3117 - 3126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Y. Chung, G. Morrone, J. J. Schuringa, B. Wong, D. C. Dorn, and M. A. S. Moore
Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis
Blood,
January 1, 2005;
105(1):
77 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. Lu, F. Li, L. Vida, and G. R. Honig
CD34+CD38- hematopoietic precursors derived from human embryonic stem cells exhibit an embryonic gene expression pattern
Blood,
June 1, 2004;
103(11):
4134 - 4141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Mestas and C. C. W. Hughes
Of Mice and Not Men: Differences between Mouse and Human Immunology
J. Immunol.,
March 1, 2004;
172(5):
2731 - 2738.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
